Primary Dysmenorreh pain severity

The study of the effects of Melatonin and Meloxicam on sleep quality and pain severity in patients with primary dysmenorreh

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015031521475N1

Enrollment

Registered

2015-07-10

Start date

2015-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Dysmenorreh. Pain and other conditions associated with female genital organs and menstrual cycle

Interventions

Intervention 1: Control group : Folic Acid 10 mg with Folate brand name of pharmaceutical manufacturer Mehr, Once at night for 5 night in the menstrual cycles before intervention and time intervention

Placebo

Treatment - Drugs

Control group : Folic Acid 10 mg with Folate brand name of pharmaceutical manufacturer Mehr, Once at night for 5 night in the menstrual cycles before intervention and time intervention

Intervention group 1 : Melatonin 3 mg of pharmaceutical manufacturer seppid drug, Once at night for 5 night in the menstrual cycles before intervention and time intervention, Chemical combination acet

Intervention group 2 : Meloxicam 7.5 mg of Manufacturer compani Loghman with mubik brand name, Once at night for 5 night, in the menstrual cycles before intervention and time intervention

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Women 18 to 35 years old and nulipar; Regular cycles 21 to 35 days; Normal BMI 19.8 to 25; Medicines and certain supplements and herbal medicines not used in before and during of the study, Exclusion criteria: Secondary dysmenorrhea from pelvic disorders; Chronic diseases; Mental disorders; Lack of person satisfaction in order to participating continue in the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Dysmenorreh Pain Severity. Timepoint: The menstrual cycle before intervention and during intervention for 5 night. Method of measurement: According to the Mac Gill pain scale ruler.;Quality Of Sleep. Timepoint: The menstrual cycle before intervention and during intervention for 5 night. Method of measurement: According to the results Acti graphic.	—

Secondary

Measure	Time frame
BMI. Timepoint: The menstrual cycle before intervention and during intervention for 5 night. Method of measurement: The result of dividing weight on the square of height.;Bed Time. Timepoint: The menstrual cycle before intervention and during intervention for 5 night. Method of measurement: According to the results Acti graphic.;The Duration Of Sleep. Timepoint: The menstrual cycle before intervention and during intervention for 5 night. Method of measurement: According to the results Acti graphic.;Waking At Night. Timepoint: The menstrual cycle before intervention and during intervention for 5 night. Method of measurement: According to the results Acti graphic.	—

Measure

Time frame

BMI. Timepoint: The menstrual cycle before intervention and during intervention for 5 night. Method of measurement: The result of dividing weight on the square of height.;Bed Time. Timepoint: The menstrual cycle before intervention and during intervention for 5 night. Method of measurement: According to the results Acti graphic.;The Duration Of Sleep. Timepoint: The menstrual cycle before intervention and during intervention for 5 night. Method of measurement: According to the results Acti graphic.;Waking At Night. Timepoint: The menstrual cycle before intervention and during intervention for 5 night. Method of measurement: According to the results Acti graphic.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farahnaz Keshavarzi

Kermanshah University of Medical Sciences

Farahnaz Keshavarzi @yahoo.com+98 83 3427 6331

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026